Spruce Biosciences Inc (SPRB)

$43.14 +0.31 (0.72%)
Market Cap 117.88M
Revenue (ttm) 0.00
Net Income (ttm) -38.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.19
Volume 48,200
Avg Vol 68,792
Day's Range N/A - N/A
Shares Out 2.75M
Stochastic %K 54%
Beta 3.16
Analysts Strong Sell
Price Target $153.28

Company Profile

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, includ...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 343 5986
Address:
611 Gateway Boulevard, Suite 740, South San Francisco, United States
IWasWrong
IWasWrong Aug. 4 at 3:32 AM
$SPRB I have $20,000 worth in shares. I'm adding more every month
0 · Reply
ShakeThatMoneyMaker
ShakeThatMoneyMaker Jul. 20 at 3:48 AM
$SPRB if there was options on this trash Id write some 25P for a few months out. This will be sub 35 by the time they get across the finish line as it slowly bleeds out. They diluted way too much and still might again but its still worth a stab after I sold at 52.
1 · Reply
NEWYORKSILVERKING
NEWYORKSILVERKING Jul. 16 at 3:10 AM
$SPRB Podcast last month with SPRB CEO..https://empoweredpatientradio.com/enzyme-replacement-therapy-for-sanfilippo-syndrome-type-b-with-dr-javier-szwarcberg-spruce-biosciences?fbclid=IwY2xjawTFKm1leHRuA2FlbQIxMABicmlkETFIa3RySlBXakE3OThyVmgzc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHqES1j6K0OVzaXUnZu0XD5itBoD8HXSCGbjY47ONwf9QAhwQKy8HkVKBoUY__aem_gjQjSyYUMNw5-fO7_CWp5g
0 · Reply
Heroforest
Heroforest Jul. 15 at 11:37 PM
$SPRB still in the accumulation phase. The price is ugly the ultimate bottom is at 30s… good luck, usually price trend up proceeding the BLA, still 4 months and Half waiting time
0 · Reply
Jyoudoit
Jyoudoit Jul. 15 at 4:44 PM
$SPRB what is happening?
0 · Reply
IWasWrong
IWasWrong Jul. 14 at 8:34 PM
$SPRB ask at 52 and the bid is at 46. This is a hedge fund walking down price with there short position.
0 · Reply
Jyoudoit
Jyoudoit Jul. 14 at 8:09 PM
$SPRB wtf was that dip? Backed by volume?
0 · Reply
Quantumup
Quantumup Jul. 13 at 12:34 PM
B Riley🏁 $SPRB and said -- We are launching coverage on Spruce Biosciences (SPRB) with a Buy rating and a $160 PT. Here's what else B Riley had to say in its initiation report: https://x.com/Quantumup1/status/2076645837942186090?s=20
0 · Reply
hbkstockislife
hbkstockislife Jul. 9 at 2:40 AM
$SPRB the most worthless stock of all time ..Nothing can make this bitch go up
1 · Reply
TopSarge
TopSarge Jun. 29 at 1:50 PM
$SPRB This one is starting to catch my eye
0 · Reply
Latest News on SPRB
Spruce Biosciences appoints Jessica Cohen Pfeffer as VP, clinical development

2026-08-03T12:17:20.000Z - 1 day ago

Spruce Biosciences appoints Jessica Cohen Pfeffer as VP, clinical development

BMRN

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

Aug 3, 2026, 8:00 AM EDT - 1 day ago

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

Spruce Biosciences appoints Quartel as Chief Medical Officer

2026-07-27T12:15:58.000Z - 8 days ago

Spruce Biosciences appoints Quartel as Chief Medical Officer

ZVRA

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

Jul 27, 2026, 8:00 AM EDT - 8 days ago

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

Spruce Biosciences initiated with a Buy at B. Riley

2026-07-13T12:15:12.000Z - 22 days ago

Spruce Biosciences initiated with a Buy at B. Riley

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

Jul 8, 2026, 4:01 PM EDT - 26 days ago

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

Spruce Biosciences joins Russell 3000 Index

2026-06-29T12:15:24.000Z - 5 weeks ago

Spruce Biosciences joins Russell 3000 Index

Spruce Biosciences Joins the Russell 3000® Index

Jun 29, 2026, 8:00 AM EDT - 5 weeks ago

Spruce Biosciences Joins the Russell 3000® Index

Spruce Biosciences appoints Agnieszka Jurecka as VP, medical affairs

2026-06-22T12:50:27.000Z - 6 weeks ago

Spruce Biosciences appoints Agnieszka Jurecka as VP, medical affairs

Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs

Jun 22, 2026, 8:00 AM EDT - 6 weeks ago

Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs

Spruce Biosciences initiated with a Buy at Guggenheim

2026-06-16T10:46:21.000Z - 7 weeks ago

Spruce Biosciences initiated with a Buy at Guggenheim

Spruce Biosciences names Eric Jordan VP, marketing, Tina Gullotta VP, finance

2026-06-15T12:17:18.000Z - 7 weeks ago

Spruce Biosciences names Eric Jordan VP, marketing, Tina Gullotta VP, finance

BBIO

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Jun 15, 2026, 8:00 AM EDT - 7 weeks ago

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Spruce Biosciences initiated with a Buy at JonesResearch

2026-06-08T20:26:36.000Z - 2 months ago

Spruce Biosciences initiated with a Buy at JonesResearch

Spruce says long-term TA-ERT data presented at MPS Symposium

2026-06-08T20:11:27.000Z - 2 months ago

Spruce says long-term TA-ERT data presented at MPS Symposium

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Jun 8, 2026, 4:05 PM EDT - 2 months ago

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Spruce Biosciences Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:05 AM EDT - 2 months ago

Spruce Biosciences Transcript: Jefferies Global Healthcare Conference 2026

Spruce Biosciences price target lowered to $150 from $200 at H.C. Wainwright

2026-06-01T10:11:46.000Z - 2 months ago

Spruce Biosciences price target lowered to $150 from $200 at H.C. Wainwright

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

May 28, 2026, 4:05 PM EDT - 2 months ago

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Spruce Biosciences to Participate in Upcoming Conferences in June

May 27, 2026, 4:05 PM EDT - 2 months ago

Spruce Biosciences to Participate in Upcoming Conferences in June

Spruce Biosciences Transcript: AGM 2026

May 21, 2026, 1:00 PM EDT - 2 months ago

Spruce Biosciences Transcript: AGM 2026

Spruce Biosciences price target lowered to $150 from $170 at Citizens

2026-05-14T09:58:05.000Z - 2 months ago

Spruce Biosciences price target lowered to $150 from $170 at Citizens

Spruce Biosciences reports Q1 EPS ($8.94), consensus ($6.11)

2026-05-13T16:56:50.000Z - 2 months ago

Spruce Biosciences reports Q1 EPS ($8.94), consensus ($6.11)

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 13, 2026, 8:00 AM EDT - 2 months ago

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

Spruce Biosciences Earnings release: Q1 2026

Spruce Biosciences Quarterly report: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 months ago

Spruce Biosciences Quarterly report: Q1 2026

Spruce Biosciences appoints Brian Walls as VP, market access

2026-05-04T12:21:00.000Z - 3 months ago

Spruce Biosciences appoints Brian Walls as VP, market access

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

May 4, 2026, 8:00 AM EDT - 3 months ago

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy

2026-04-27T14:10:40.000Z - 3 months ago

Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy

DNLI

Spruce Biosciences initiated with a Buy at Craig-Hallum

2026-04-27T12:11:23.000Z - 3 months ago

Spruce Biosciences initiated with a Buy at Craig-Hallum

Spruce Biosciences 1.15M share Spot Secondary priced at $50.00

2026-04-21T11:08:06.000Z - 3 months ago

Spruce Biosciences 1.15M share Spot Secondary priced at $50.00

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Apr 20, 2026, 11:45 PM EDT - 3 months ago

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences down 13% at $60.50 after equity offering announcement

2026-04-20T20:52:59.000Z - 3 months ago

Spruce Biosciences down 13% at $60.50 after equity offering announcement

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Apr 20, 2026, 4:01 PM EDT - 3 months ago

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Spruce Biosciences Proxy statement: Proxy filing

Spruce Biosciences Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Spruce Biosciences Proxy statement: Proxy filing

Spruce Biosciences Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 12:30 PM EDT - 5 months ago

Spruce Biosciences Transcript: The Citizens Life Sciences Conference 2026

Spruce Biosciences Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 11:20 AM EDT - 5 months ago

Spruce Biosciences Transcript: Leerink Global Healthcare Conference 2026

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Mar 9, 2026, 7:05 AM EDT - 5 months ago

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Spruce Biosciences Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Spruce Biosciences Earnings release: Q4 2025

Spruce Biosciences Annual report: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Spruce Biosciences Annual report: Q4 2025

Spruce Biosciences Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Spruce Biosciences Slides: Corporate presentation

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Mar 2, 2026, 4:05 PM EST - 5 months ago

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Spruce Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 3:20 PM EST - 5 months ago

Spruce Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Feb 18, 2026, 7:00 AM EST - 5 months ago

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 4:05 PM EST - 5 months ago

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Feb 5, 2026, 4:05 PM EST - 6 months ago

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Feb 3, 2026, 8:00 AM EST - 6 months ago

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Jan 28, 2026, 8:00 AM EST - 6 months ago

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Jan 18, 2026, 7:02 PM EST - 7 months ago

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Jan 8, 2026, 8:00 AM EST - 7 months ago

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Dec 15, 2025, 8:00 AM EST - 8 months ago

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 10, 2025, 4:05 PM EST - 9 months ago

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 9 months ago

Spruce Biosciences Earnings release: Q3 2025

Spruce Biosciences Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 9 months ago

Spruce Biosciences Quarterly report: Q3 2025

Spruce Biosciences Registration statement: Registration Filing

Oct 29, 2025, 8:00 AM EDT - 9 months ago

Spruce Biosciences Registration statement: Registration Filing

Spruce Biosciences Registration statement: Registration Filing

Oct 29, 2025, 8:00 AM EDT - 9 months ago

Spruce Biosciences Registration statement: Registration Filing

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Oct 7, 2025, 9:44 AM EDT - 10 months ago

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Oct 6, 2025, 8:00 AM EDT - 10 months ago

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

Sep 15, 2025, 7:00 AM EDT - 11 months ago

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

IWasWrong
IWasWrong Aug. 4 at 3:32 AM
$SPRB I have $20,000 worth in shares. I'm adding more every month
0 · Reply
ShakeThatMoneyMaker
ShakeThatMoneyMaker Jul. 20 at 3:48 AM
$SPRB if there was options on this trash Id write some 25P for a few months out. This will be sub 35 by the time they get across the finish line as it slowly bleeds out. They diluted way too much and still might again but its still worth a stab after I sold at 52.
1 · Reply
NEWYORKSILVERKING
NEWYORKSILVERKING Jul. 16 at 3:10 AM
$SPRB Podcast last month with SPRB CEO..https://empoweredpatientradio.com/enzyme-replacement-therapy-for-sanfilippo-syndrome-type-b-with-dr-javier-szwarcberg-spruce-biosciences?fbclid=IwY2xjawTFKm1leHRuA2FlbQIxMABicmlkETFIa3RySlBXakE3OThyVmgzc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHqES1j6K0OVzaXUnZu0XD5itBoD8HXSCGbjY47ONwf9QAhwQKy8HkVKBoUY__aem_gjQjSyYUMNw5-fO7_CWp5g
0 · Reply
Heroforest
Heroforest Jul. 15 at 11:37 PM
$SPRB still in the accumulation phase. The price is ugly the ultimate bottom is at 30s… good luck, usually price trend up proceeding the BLA, still 4 months and Half waiting time
0 · Reply
Jyoudoit
Jyoudoit Jul. 15 at 4:44 PM
$SPRB what is happening?
0 · Reply
IWasWrong
IWasWrong Jul. 14 at 8:34 PM
$SPRB ask at 52 and the bid is at 46. This is a hedge fund walking down price with there short position.
0 · Reply
Jyoudoit
Jyoudoit Jul. 14 at 8:09 PM
$SPRB wtf was that dip? Backed by volume?
0 · Reply
Quantumup
Quantumup Jul. 13 at 12:34 PM
B Riley🏁 $SPRB and said -- We are launching coverage on Spruce Biosciences (SPRB) with a Buy rating and a $160 PT. Here's what else B Riley had to say in its initiation report: https://x.com/Quantumup1/status/2076645837942186090?s=20
0 · Reply
hbkstockislife
hbkstockislife Jul. 9 at 2:40 AM
$SPRB the most worthless stock of all time ..Nothing can make this bitch go up
1 · Reply
TopSarge
TopSarge Jun. 29 at 1:50 PM
$SPRB This one is starting to catch my eye
0 · Reply
Merlintrader
Merlintrader Jun. 25 at 3:03 PM
$UNCY Top priority! Russell 2026 Biotech Watchlist: , $GALT, $SPRB, $OVID and the Small-Cap Health Care Additions to Watch https://www.merlintrader.com/russell-2026-biotech-watchlist/
0 · Reply
CatHerder69
CatHerder69 Jun. 24 at 10:07 PM
$ADTX I sat on bags $SPRB for years and they were delisted to OTC in 2025 and I sold at over $360. Anything can happen.
1 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jun. 22 at 10:28 PM
$MU $APGE $SPRB profits to VSEE
0 · Reply
djred
djred Jun. 18 at 5:56 PM
$SPRB Is there talks of a buyout? or is the main catalyst to watch out for in Q4 2026?
0 · Reply
parbv
parbv Jun. 18 at 1:57 PM
$SPRB Really crazy at this level. My only concern is potential competition from JCR down the road, but even they are several years behind.
0 · Reply
DARKP00L
DARKP00L Jun. 16 at 1:27 PM
$SPRB 08:32 on Jun. 16 2026 Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123 #tradeideas
1 · Reply
SuperGreenToday
SuperGreenToday Jun. 15 at 3:13 PM
$SPRB
0 · Reply
HenrikTheBandit
HenrikTheBandit Jun. 12 at 2:50 PM
$SPRB $225
0 · Reply
Rounderssss4
Rounderssss4 Jun. 12 at 2:49 PM
$SPRB buyout weekend
1 · Reply
Rounderssss4
Rounderssss4 Jun. 12 at 2:48 PM
$SPRB 👀
0 · Reply
HenrikTheBandit
HenrikTheBandit Jun. 12 at 2:22 PM
$SPRB buy out
0 · Reply
Rounderssss4
Rounderssss4 Jun. 10 at 12:37 PM
$CELC need 💯 today bring $SPRB up to 💯 too.
0 · Reply